Background/Objectives: Melanoma apps are
INTRODUCTION
A growing number of smartphone applications, or apps, claim to automatically assess the risk of skin lesions developing into skin cancer. These apps (melanoma apps) assess smartphone photographs of pigmented lesions using underlying proprietary algorithms, without clinician involvement. A review of melanoma prevention and detection apps conducted in 2015 1 found 39 different apps that could be categorised as either educational apps, diary apps storing photos for comparison, store and forward teledermatology apps and melanoma apps.
In the absence of population-based screening for melanoma, people are advised to monitor their skin, searching for new or changed moles, and see a doctor when they are concerned. Melanoma apps could aid consumers in assessing the risk of a pigmented skin lesion 2 and could potentially improve the quality of patients' skin self examinations (SSE) . However, the current literature suggests that melanoma apps have poor diagnostic accuracy for melanoma. Previous studies have reported sensitivity and specificity of melanoma apps ranging from 0 to 70% and 30 to 93.7%, respectively. 3 Worryingly, these sensitivities and specificities were in some cases even lower than patient SSE alone, which has a reported sensitivity ranging from 25 to 93% and a specificity 83 to 97%. 4 A major limitation of previous studies of melanoma apps is the use of archived images or high-resolution printouts, 3, 5, 6 rather than photographing lesions in vivo, as is their intended use. This is particularly relevant given that the diagnostic capabilities of some melanoma apps may be influenced by lighting, angles of imaging, hair and other aberrations of surrounding skin. 7 An ever-evolving app market also means much of the previous research is now outdated. This study's primary aim is to provide an up-to-date evaluation of the melanoma apps, focusing specifically on their ability to accurately risk-stratify pigmented lesions in vivo compared with clinical assessment by dermatologists.
METHODS
Ethics approval for this study was granted by the ethics committee of the Metro South Hospital and Health Service (HREC/14/QPAH/473) and the University of Queensland (no. 2014001372). The study was registered with the Australian and New Zealand Clinical Trials Registry (no. ACTRN12615000268549). This study is reported in accordance with the Standards for Reporting of Diagnostic Accuracy checklist. 8 
Participants
A convenience sample was recruited between 23 March 2015 and 12 July 2016 from the Princess Alexandra Hospital Dermatology Outpatients Department surgical list and participants in the pigmentation genotypes and phenotypic correlations with dermoscopic naevus types and distribution study (HREC/09/QPAH/162 and HREC/09/QPAH/126), abbreviated to the Brisbane naevus morphology study (BNMS). These recruitment methods were used to ensure the apps would be tested on a range of pigmented lesion types. The target sample size was 30 participants for this pilot study. Surgical list patients were included if they had a pigmented lesion scheduled for excision, excluding lesions on non-typical skin surfaces (e.g. the lip). Each participant provided at least one, and a maximum of five, pigmented lesions to prevent any individual disproportionately affecting results.
Selection of tested apps and devices
App stores for each operating system (iOS and android) were searched for melanoma apps using search terms 'skin,' 'skin cancer,' 'melanoma,' 'mole,' 'mole checker' and 'mole scan.' Apps were included only if they provided an overall risk stratification for lesions analysed, English instructions and did not require clinician involvement (i.e. telediagnosis). Apps were excluded if they were cosmetically oriented, only educational in nature or required a dermatoscope.
Three apps were identified. SkinVision (Amsterdam, the Netherlands) had both an iOS version and an android version. SpotMole (Cooclea, Barcelona, Spain) was available only on android but had two image submission modes; direct submission of images captured within the app and indirect submission of images from the smartphone image gallery. Only the android version of Dr Mole (Revosoft Technologies, Sydney, NSW, Australia) was included, as the iOS version did not provide an overall risk assessment of pigmented lesions.
Testing of apps
Images of each lesion were captured and analysed by the melanoma apps according to the instructions provided (Table 1) . They were used in consistent order each timeSkinVision iOS, SkinVision android, SpotMole, direct submission, SpotMole, indirect submission and Dr Mole android. For any lesion an app reported as being 'unable to be analysed' up to 10 attempts were made. 5 After this, the lesion was recorded as unevaluable for this app. Due to the recruitment and data collection methods the primary researcher could not be blinded to the app or lesion types.
Assessment of pigmented lesions by two independent dermatologists
To define the clinical risk of each lesion in a standardised way dermoscopic images of each lesion were taken using a Canfield VEOS Dermatoscope (Canfield Scientific, Parsippany, NJ, USA). These images were collated and then provided to two consultant dermatologists. The clinicians were instructed to define lesions in three ways: suspicious if they felt the lesion was of high enough risk to warrant an in-person consultation; benign for lesion that did not meet the suspicious threshold; and unsuitable for clinical assessment if the image was of not high enough quality to comment. The dermatologists conducted these assessments independently and were not given any information beyond the image itself.
Assessment of pigmented lesions by mobile applications
Details of how each app was used and how positive and negative results were defined are shown in Table 1 . Two examples of how dermatologist clinical assessment compared with the assessment provided by the melanoma apps can be seen in Table 2 .
For SkinVision and SpotMole, a positive result indicates the app recommended that the individual see a clinician for the pigmented lesion ( Table 1 ). The Dr Mole android differed in that the results were presented as a horizontal bar, with shading representing a proportion of risk ( Fig. 1 ).
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A Ngoo et al. This level of risk was converted to a numerical variable by measuring the proportion of the bar shaded and assigning the appropriate percentage. A receiver operator curve (ROC) analysis was performed and Youden's index was calculated to determine that 73% of the bar being filled represented the threshold at which the sensitivity and specificity of the app in relation to the clinician's assessment of the lesion was optimised. Thus, for the Dr Mole android, a true positive result indicated the app had assigned >73% risk to any lesion the dermatologist had defined as clinically suspicious (Table 1) .
Statistical analysis
Patients' and lesions' characteristics were summarised using descriptive statistics. Sensitivity and specificity were calculated using McNemar's test for two by two tables plotting true and false positives and negatives. Clustering of lesions within patients was adjusted for via ratio estimator and variance inflation factor methods, as detailed by Genders and colleagues. 9 A modified Excel spreadsheet was provided by these authors to obtain the adjusted confidence intervals. Level of agreement between a clinician assessment and the apps tested was determined using Kappa Statistics. Terminology for values was defined as by Landis and Koch (≥0.10 disagreement, À0.10 to 0.00 no agreement, 0.00 poor, 0.00-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial, 0.81-1.00 almost perfect). 10, 11 All data analysis was performed using IBM SPSS vers. 23 (IBM, Armonk, NY, USA).
RESULTS
In total, 38 participants were recruited; 26 from the Princess Alexandra Hospital dermatology outpatients department surgical list and 12 from the Brisbane naevus morphology study. Eight participants were excluded; four with poor quality images; one with a lesion on their lip; two with keratinocyte lesions; one as they later declined excision of the lesion (Fig. 2) . After exclusions there were 30 participants; 18 from the surgical list and 12 from the Brisbane naevus morphology study ( Table 3 ). The participants' ages ranged from 28 to 86 years and 43% (n = 13) were men. One participant was Filipino while all others were Caucasian. These participants provided 57 pigmented lesions, 42 of which were deemed clinically suspicious and 15 clinically benign, as defined by the dermatologists' assessment of the clinical and dermoscopic images. The histopathology results indicated that one included lesion was a melanoma in situ.
Of the lesions the SkinVision iOS and SkinVision android were unable to analyse 14% (n = 8; five clinically A Ngoo et al. Smartphone apps for pigmented lesions e179 suspicious, three clinically benign) and 18% (n = 10, five clinically suspicious; five clinically benign), respectively. SpotMole via direct and indirect submission and Dr Mole android were able to analyse all lesions. The sensitivity of the melanoma apps ranged from 21 to 72% and the specificity from 27 to 100% (Table 4) . SkinVision on iOS and android recommended a clinician review (positive result) for 27 and 34 lesions, respectively. This resulted in limited agreement with clinician decisions, with SkinVision iOS having an overall concordance of 55% (j = 0.05, SE = 0.13, P = 0.68) and SkinVision android 62% (j = À0.01, SE = 0.15, P = 0.97).
The concordance of SpotMole direct and indirect submission results with clinicians was 53% (j = 0.16, SE = 0.10, P = 0.12) and 51% (j = 0.113, SE = 0.10, P = 0.27), respectively.
Dr Mole android had a specificity of 100% by categorising all clinically suspicious lesions as low risk, resulting in 33/42 false negatives and a low sensitivity of 21%. Concordance with clinicians was 42% (j = 0.13, SE = 0.05, P = 0.05) indicating slight agreement with clinician assessment. ROC analysis indicated that the app's ability to determine if a pigmented lesion was high or low risk was close to chance 12 (area under ROC curve = 0.52, 95% CI 0.35-0.70).
Only one melanoma in situ was imaged over the course of the study. All app versions apart from Dr Mole android diagnosed the lesion as clinically suspicious or high risk.
DISCUSSION
There was limited agreement between assessment of skin lesions by melanoma apps and the clinical decisions of dermatologists based on review of dermoscopic images. This study supports previous literature urging consumer caution when using these apps. 3, 5, [13] [14] [15] Even when imaging pigmented lesions in vivo, in the context the apps were intended to be used, the apps' ability to assess risk of individual lesions is still limited. Regardless of the image submission method or device used, all included apps had low overall agreement with dermatologists' clinical decisions. It is unclear if melanoma apps would add benefit to patient SSE for detecting skin cancers. A broad review of SSE by Hamidi and colleagues 4 in 2010 comparing SSE to clinician diagnosis found SSE's sensitivity ranged from 25 to 93% and its specificity from 83 to 97%. 4 In comparison, SpotMole had a sensitivity of 43% (95% CI 27.9-57.8) and a specificity of 80% (95% CI 59.8-100.0). Comparing these two studies, while imperfect, is informative. It may suggest that in some cases, even the best performing app, SpotMole, is less effective than patient-unaided SSE at determining which lesions a dermatologist would deem as a high and low risk.
Little is known about how consumers interact with and respond to melanoma apps. Specifically, it is unknown how consumers would respond if the app failed to analyse an image or how they might respond to receiving reassurance that a lesion is benign when in fact it requires excision. SkinVision was unable to analyse between 14-18% of pigmented lesions submitted, an issue that has been previously reported. 7 While it could be suggested that the apps perform better when ideal images are submitted, the aim of this study was to test the apps in a real-world scenario. The researcher took a standardised approach to imaging; by using a detailed standardised protocol and taking up to 10 images of an individual lesion if previous images could not be analysed. It is unknown whether the proportion of unanalysable images may be even higher in the community, when inexperienced app users try to submit photos. One may infer that the inability to analyse lesions would be a significant limitation to the app's use in practice. Nevertheless, the degree to which this impacts on the utility of these melanoma apps is unclear due to lack of research in this area. It is also problematic that some melanoma apps lack clear recommendations on how patients should respond to results provided. For SpotMole, whether a lesion was deemed okay or problematic, the app advised consumers to contact their doctor if they were concerned, in effect voiding the meaningfulness of the results. Dr Mole android was similarly equivocal; the app filled a bar to represent the overall risk though did not specify the risk level at which patients should seek medical consultation (Fig. 1) . Dr Mole android states it is intended for educational purposes only and that patients should see their doctor irrespective of the overall risk determined by the app, yet it has been marketed in the media as a diagnostic app. 16 At the time of writing, the app has become unavailable on the app stores.
Limitations
Only one participant was diagnosed with melanoma in situ. All other lesions were histopathologically confirmed as benign or, for those not excised, were deemed clinically benign by dermatologist review. Interestingly, 
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A Ngoo et al. the melanoma in situ was appropriately stratified as high risk by all apps apart from the Dr Mole android. This result highlights the need for further research. While the limitations of melanoma apps compared with a dermatologist's review of lesions are clear, we cannot make conclusions about the apps' ability to detect melanoma, based on the results from this study. Furthermore, while the study was designed to replicate the image capture and upload process as it would be performed by users in general, this study ultimately involved only one individual performing the imaging. While all steps were taken to ensure the ideal and standardised imaging protocol was followed in the testing of all apps, it is obviously possible that some images may have been taken imperfectly. Despite this, experience with and repeated use of the apps may have led to the primary researcher to have better than average use. Potentially, this study could thus have overestimated the capabilities of melanoma apps. Conversely, as the primary researcher could not be blinded to the apps or the pigmented lesions themselves, inadvertent bias in the app use and results cannot be ruled out.
Relevance to clinical practice and research
There is not high enough agreement between melanoma apps and the study dermatologists' decisions to be considered a substitute for clinicians' review at this stage. Importantly, the apps do not appear to provide benefit to users in addition to that of unaided SSE. This issue is even more significant given that some apps lack clear guidelines on how users should respond to the results and they are currently unable to analyse a proportion of pigmented lesions submitted to them. These issues identified are all the more concerning, given that all apps are paid for privately and cost consumers between Australian $7 to 30.
However, this study does not suggest melanoma apps are directly harmful or that they fail to provide any overall benefit to users. It has been previously asserted that apps may improve health outcomes by streamlining the SSE process and rewarding consumers with fast feedback on lesions they are concerned about. 7 Moreover, the apps may educate users about skin cancer and aid them in keeping track of skin changes. 7 Put together, this study demonstrates that currently available melanoma apps that automatically assess pigmented lesions by algorithms submitted via a smartphone camera are not yet accurate enough to be used to independently assess pigmented skin lesions, and they may not offer benefit to consumers above that of normal SSE. While it is expected that the capabilities of melanoma apps will improve with technological advances and increased demand for consumer-driven health care in future, it will be important to continue to test these apps in real-world scenarios with clinicians and consumers, and also to examine how users respond to the information these apps provide.
